Molecular epidemiology of hepatitis B anc C viruses for the development of individualised therapeutic vaccines
Funding: Latvian Council of Science Colaboration project # 10.0029. "Innovative approaches for the investigation of molecular genetic properties of microorganisms and mechanisms of related systemic damage, and for the development of individualised monitoring, diagnosis and therapy of infectious diseases"
Subproject manager: Dr. habil. biol. Pauls Pumpēns
Molecularly-epidemiologic background will be created for development of new vaccination strategy- individualized therapeutic vaccines (ITV). For ITV development, information about B, T and CTL epitopes of HBV and HCV variants of patients from Latvian Infectology Centre (LIC). For this purpose HBV (preS+S, C, P, X) and HCV (core, E1, E2, NS3, NS5) genome regions will be sequenced. HBV core-antigen (HBc) will be used as a virus like particle (VLP) platform for ITV development. For the most suitable VLP vector selection, HBc genes from LIC patients will be cloned and expressed in E.coli. HBc genes from LIC patients will significantly differ from well known HBc prototypes. Will be compared self-assembling, stability and vector capacity with standard HBc vectors used in BMC. The best vectors will be used for model-epitope (HBV preS1 and HCV HVR1) insertion tests.